|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ding YM, Dong JH, Chen LL and Zhang HD:
Increased expression of galectin-1 is associated with human oral
squamous cell carcinoma development. Oncol Rep. 21:983–987.
2009.PubMed/NCBI
|
|
3
|
Yang Y, Rhodus NL, Ondrey FG, Wuertz BR,
Chen X, Zhu Y and Griffin TJ: Quantitative proteomic analysis of
oral brush biopsies identifies secretory leukocyte protease
inhibitor as a promising, mechanism-based oral cancer biomarker.
PLoS One. 9:e953892014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bouchard D, Morisset D, Bourbonnais Y and
Tremblay GM: Proteins with whey-acidic-protein motifs and cancer.
Lancet Oncol. 7:167–174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cordes C, Häsler R, Werner C, Görögh T,
Röcken C, Hebebrand L, Kast WM, Hoffmann M, Schreiber S and
Ambrosch P: The level of secretory leukocyte protease inhibitor is
decreased in metastatic head and neck squamous cell carcinoma. Int
J Oncol. 39:185–191. 2011.PubMed/NCBI
|
|
6
|
Scott A, Weldon S and Taggart CC: SLPI and
elafin: Multifunctional antiproteases of the WFDC family. Biochem
Soc Trans. 39:1437–1440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Williams SE, Brown TI, Roghanian A and
Sallenave JM: SLPI and elafin: One glove, many fingers. Clin Sci.
110:21–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie
X, Tang Z and Jiang X: Secretory leukocyte protease inhibitor is a
proliferation and survival factor for pancreatic cancer cells. Clin
Transl Oncol. 17:314–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng WL, Wang CS, Huang YH, Liang Y, Lin
PY, Hsueh C, Wu YC, Chen WJ, Yu CJ, Lin SR and Lin KH:
Overexpression of a secretory leukocyte protease inhibitor in human
gastric cancer. Int J Cancer. 123:1787–1796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brodt P, Fallavollita L, Khatib AM, Samani
AA and Zhang D: Cooperative regulation of the invasive and
metastatic phenotypes by different domains of the type I
insulin-like growth factor receptor beta subunit. J Biol Chem.
276:33608–33615. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jan Treda C, Fukuhara T, Suzuki T,
Nakamura A, Zaini J, Kikuchi T, Ebina M and Nukiwa T: Secretory
leukocyte protease inhibitor modulates urethane-induced lung
carcinogenesis. Carcinogenesis. 35:896–904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Velarde MC, Parisek SI, Eason RR, Simmen
FA and Simmen RC: The secretory leukocyte protease inhibitor gene
is a target of epidermal growth factor receptor action in
endometrial epithelial cells. J Endocrinol. 184:141–151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsukishiro S, Suzumori N, Nishikawa H,
Arakawa A and Suzumori K: Use of serum secretory leukocyte protease
inhibitor levels in patients to improve specificity of ovarian
cancer diagnosis. Gynecol Oncol. 96:516–519. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tse KP, Wu CS, Hsueh C, Chang KP, Hao SP,
Chang YS and Tsang NM: The relationship between secretory leukocyte
protease inhibitor expression and Epstein-Barr virus status among
patients with nasopharyngeal carcinoma. Anticancer Res.
32:1299–1307. 2012.PubMed/NCBI
|
|
15
|
Quabius ES, Görögh T, Fischer GS, Hoffmann
AS, Gebhard M, Evert M, Beule A, Maune S, Knecht R, Óvári A, et al:
The antileukoprotease secretory leukocyte protease inhibitor (SLPI)
and its role in the prevention of HPV-infections in head and neck
squamous cell carcinoma. Cancer Lett. 357:339–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosso M, Lapyckyj L, Amiano N, Besso MJ,
Sánchez M, Chuluyan E and Vazquez-Levin MH: Secretory Leukocyte
Protease Inhibitor (SLPI) expression downregulates E-cadherin,
induces β-catenin re-localisation and triggers apoptosis-related
events in breast cancer cells. Biol Cell. 106:308–322. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simpkins FA, Devoogdt NM, Rasool N, Tchabo
NE, Alejandro EU, Kamrava MM and Kohn EC: The alarm anti-protease,
secretory leukocyte protease inhibitor, is a proliferation and
survival factor for ovarian cancer cells. Carcinogenesis.
29:466–472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen J, Nikitakis NG, Chaisuparat R,
Greenwell-Wild T, Gliozzi M, Jin W, Adli A, Moutsopoulos N, Wu T,
Warburton G and Wahl SM: Secretory leukocyte protease inhibitor
(SLPI) expression and tumor invasion in oral squamous cell
carcinoma. Am J Pathol. 178:2866–2878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sano C, Shimizu T and Tomioka H: Effects
of secretory leukocyte protease inhibitor on the tumor necrosis
factor-alpha production and NF-kappaB activation of
lipopolysaccharide-stimulated macrophages. Cytokine. 21:38–42.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lentsch AB, Jordan JA, Czermak BJ, Diehl
KM, Younkin EM, Sarma V and Ward PA: Inhibition of NF-kappaB
activation and augmentation of IkappaBbeta by secretory leukocyte
protease inhibitor during lung inflammation. Am J Pathol.
154:239–247. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mikami Y, Iwase T, Komiyama Y, Matsumoto
N, Oki H and Komiyama K: Secretory leukocyte protease inhibitor
inhibits expression of polymeric immunoglobulin receptor via the
NF-κB signaling pathway. Mol Immunol. 67:568–574. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barkett M and Gilmore TD: Control of
apoptosis by Rel/NF-kappaB transcription factors. Oncogene.
18:6910–6924. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf
JS, Brown K, Siebenlist U and Van Waes C: Expression of a
dominant-negative mutant inhibitor-kappaBalpha of nuclear
factor-kappaB in human head and neck squamous cell carcinoma
inhibits survival, proinflammatory cytokine expression, and tumor
growth in vivo. Cancer Res. 59:3468–3474. 1999.PubMed/NCBI
|
|
24
|
Nottingham LK, Yan CH, Yang X, Si H,
Coupar J, Bian Y, Cheng TF, Allen C, Arun P, Gius D, et al:
Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce
EGFR/AP1 signaling to promote survival and migration of head and
neck cancer. Oncogene. 33:1135–1147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf
JS, Crowl-Bancroft CV, Mukaida N and Van Waes C: Constitutive
activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6
in human head and neck squamous cell carcinoma cell lines that
express pro-inflammatory and pro-angiogenic cytokines. Mol
Carcinog. 26:119–129. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu H, Zhu R, Liu C, Ma R, Wang L, Chen B,
Li L, Niu J, Zhao D, Mo F, et al: Evaluation of decalcification
techniques for rat femurs using HE and immunohistochemical
staining. Biomed Res Int. 2017:90507542017.PubMed/NCBI
|
|
27
|
Cai B, Miao Y and Liu Y, Xu X, Guan S, Wu
J and Liu Y: Nuclear multidrug-resistance related protein 1
contributes to multidrug-resistance of mucoepidermoid carcinoma
mainly via regulating multidrug-resistance protein 1: A human
mucoepidermoid carcinoma cells model and Spearman's rank
correlation analysis. PLoS One. 8:e696112013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dalley AJ, Pitty LP, Major AG, Abdulmajeed
AA and Farah CS: Expression of ABCG2 and Bmi-1 in oral potentially
malignant lesions and oral squamous cell carcinoma. Cancer Med.
3:273–283. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okamoto A, Higo M, Shiiba M, Nakashima D,
Koyama T, Miyamoto I, Kasama H, Kasamatsu A, Ogawara K, Yokoe H, et
al: Down-regulation of nucleolar and spindle-associated protein 1
(NUSAP1) expression suppresses tumor and cell proliferation and
enhances anti-tumor effect of paclitaxel in oral squamous cell
carcinoma. PLoS One. 10:e01422522015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu S, Ye D, Guo W, Yu W, He Y, Hu J, Wang
Y, Zhang L, Liao Y, Song H, et al: G9a is essential for
EMT-mediated metastasis and maintenance of cancer stem cell-like
characters in head and neck squamous cell carcinoma. Oncotarget.
6:6887–6901. 2015.PubMed/NCBI
|
|
31
|
Taggart CC, Cryan SA, Weldon S, Gibbons A,
Greene CM, Kelly E, Low TB, O'neill SJ and McElvaney NG: Secretory
leucoprotease inhibitor binds to NF-kappaB binding sites in
monocytes and inhibits p65 binding. J Exp Med. 202:1659–1668. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Westin U, Nyström M, Ljungcrantz I,
Eriksson B and Ohlsson K: The presence of elafin, SLPI, IL1-RA and
STNFalpha RI in head and neck squamous cell carcinomas and their
relation to the degree of tumour differentiation. Mediators
Inflamm. 11:7–12. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rasool N, LaRochelle W, Zhong H, Ara G,
Cohen J and Kohn EC: Secretory leukocyte protease inhibitor
antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res.
16:600–609. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Devoogdt N, Hassanzadeh Ghassabeh G, Zhang
J, Brys L, De Baetselier P and Revets H: Secretory leukocyte
protease inhibitor promotes the tumorigenic and metastatic
potential of cancer cells. Proc Natl Acad Sci USA. 100:pp.
5778–5782. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng D, Gui B, Gray KP, Tinay I, Rafiei
S, Huang Q, Sweeney CJ, Kibel AS and Jia L: Secretory leukocyte
protease inhibitor is a survival and proliferation factor for
castration-resistant prostate cancer. Oncogene. 35:4807–4815. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakamura K, Takamoto N, Hongo A, Kodama J,
Abrzua F, Nasu Y, Kumon H and Hiramatsu Y: Secretory leukoprotease
inhibitor inhibits cell growth through apoptotic pathway on ovarian
cancer. Oncol Rep. 19:1085–1091. 2008.PubMed/NCBI
|
|
37
|
Amiano NO, Costa MJ, Reiteri RM, Payés C,
Guerrieri D, Tateosian NL, Sánchez ML, Maffia PC, Diament M, Karas
R, et al: Anti-tumor effect of SLPI on mammary but not colon tumor
growth. J Cell Physiol. 228:469–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Amiano N, Reiteri RM, Costa MJ, Tateosian
N and Chuluyan HE: Immunotherapy with SLPI over-expressing mammary
tumor cells decreases tumor growth. Cancer Immunol Immunother.
60:895–900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi BD, Jeong SJ, Wang G, Park JJ, Lim
DS, Kim BH, Cho YI, Kim CS and Jeong MJ: Secretory leukocyte
protease inhibitor is associated with MMP-2 and MMP-9 to promote
migration and invasion in SNU638 gastric cancer cells. Int J Mol
Med. 28:527–534. 2011.PubMed/NCBI
|
|
40
|
Devoogdt N, Rasool N, Hoskins E, Simpkins
F, Tchabo N and Kohn EC: Overexpression of protease inhibitor-dead
secretory leukocyte protease inhibitor causes more aggressive
ovarian cancer in vitro and in vivo. Cancer Sci.
100:434–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z,
Gao N, Zhang YY and Chen QM: In vitro and clinical studies of gene
therapy with recombinant human adenovirus-p53 injection for oral
leukoplakia. Clin Cancer Res. 15:6724–6731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsuzuki H, Fujieda S, Sunaga H, Narita N,
Tokuriki M and Saito H: Expression of p27 and apoptosis in oral
leukoplakia. Anticancer Res. 23:1265–1270. 2003.PubMed/NCBI
|
|
43
|
Taggart CC, Greene CM, McElvaney NG and
O'Neill S: Secretory leucoprotease inhibitor prevents
lipopolysaccharide-induced IkappaBalpha degradation without
affecting phosphorylation or ubiquitination. J Biol Chem.
277:33648–33653. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bindhu OS, Ramadas K, Sebastian P and
Pillai MR: High expression levels of nuclear factor kappa B and
gelatinase in the tumorigenesis of oral squamous cell carcinoma.
Head Neck. 28:916–925. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pontes HA, Pontes FS, Fonseca FP, de
Carvalho PL, Pereira EM, de Abreu MC, de Freitas Silva BS and dos
Santos Pinto D Jr: Nuclear factor κB and cyclooxygenase-2
immunoexpression in oral dysplasia and oral squamous cell
carcinoma. Ann Diagn Pathol. 17:45–50. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Irmler M, Steiner V, Ruegg C, Wajant H and
Tschopp J: Caspase-induced inactivation of the anti-apoptotic TRAF1
during Fas ligand-mediated apoptosis. Febs Lett. 468:129–133. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee SY and Choi Y: TRAF1 and its
biological functions. Adv Exp Med Biol. 597:25–31. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang CY, Mayo MW, Korneluk RG, Goeddel DV
and Baldwin AS Jr: NF-kappaB antiapoptosis: Induction of TRAF1 and
TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281:1680–1683. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Speiser DE, Lee SY, Wong B, Arron J,
Santana A, Kong YY, Ohashi PS and Choi Y: A regulatory role for
TRAF1 in antigen-induced apoptosis of T cells. J Exp Med.
185:1777–1783. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wan XK, Yuan SL, Tao HX, Diao LP, Wang YC,
Cao C and Liu CJ: The upregulation of TRAF1 induced by helicobacter
pylori plays an antiapoptotic effect on the infected cells.
Helicobacter. 21:554–564. 2016. View Article : Google Scholar : PubMed/NCBI
|
